Latest issueOakland's Jwalt, 24, makes Grammy history with a nominationRead now

Classes & TalksThursday, December 10

Danette Daniels: Towards new cancer medicines with degraders of chromatin regulatory proteins

Thursday, December 10 · 11 a.m.-12 p.m. · 125 Li Ka Shing Center

11 a.m.-12 p.m.
When
  • Thursday, December 10 · 11 a.m.-12 p.m.
Where
125 Li Ka Shing CenterBerkeley, CA

The event’s page Add to my calendarOpen in Maps

About this event

Targeted protein degradation as a therapeutic modality has experienced an explosion in research the past several years resulting in advancements of numerous degraders to the clinic addressing a wide variety of disease indications. The strengths of this induced proximity modality include its catalytic mechanism, the ability to drug non-enzymatic targets which serve as scaffolds, and introduction of selectivity amongst paralog family members. In this talk, we will highlight our work developing highly selective and potent degraders to CREB binding protein (CBP), E1A binding protein (EP300), and a historically intractable target, ARID1B. Each of these targets regulate a myriad of cellular processes and have been implicated in numerous oncology diseases. CBP and EP300 are two paralog histone acetyltransferases and while several classes of inhibitors have been developed to CBP/EP300, they have dual activity leading to tolerability challenges. Meanwhile, ARID1B, a core component of the SWI/SNF chromatin remodeling complex, has long been considered undruggable due to the absence of known binders and lack of ligandable pockets. Striking dependency on ARID1B is observed across multiple cancer indications harboring ARID1A mutations, highlighting a synthetic lethal relationship between these paralogs. In this talk I will highlight the mechanisms for which enabled development of binders and subsequently selective degraders to each other these targets. With these selective compounds in hand, we then demonstrate strong anti-proliferative effects and for CBP and EP300, in vivo tumor growth inhibition across numerous oncology indications with an improved therapeutic window as compared to dual inhibition.Division(s): MTx (Molecular Therapeutics)ition.

Division(s): MTx (Molecular Therapeutics)

Listed by CitySpark: Berkeley, CA, gathered by the Oakland events calendar.

Does something look wrong?

Promote

Location

125 Li Ka Shing Center125 Li Ka Shing Center · Berkeley, CA

Get directions